On May 10, 2026, TÜV Rheinland issued a technical notice mandating additional ISO 10993-5 and ISO 10993-10 biocompatibility testing for in vitro diagnostic (IVD) monitoring modules made of poly-4-methyl-1-pentene (PMP)—including blood gas analyzer sensor housings and ECMO flow monitoring components—intended for CE marking under the EU IVDR. This development directly affects IVD instrument manufacturers, especially those in China exporting to the EU, and signals potential shifts in material qualification requirements and PMP supply chain practices.

Event Overview

On May 10, 2026, TÜV Rheinland published a technical bulletin stating that PMP-based IVD monitoring modules used in critical applications such as blood gas analysis and extracorporeal membrane oxygenation (ECMO) flow monitoring must submit supplementary ISO 10993-5 (cytotoxicity) and ISO 10993-10 (irritation and sensitization) test reports to support CE conformity assessment under Regulation (EU) 2017/746 (IVDR). The notice is publicly available and applies to new submissions and pending applications where PMP is used in direct or indirect patient-contact components.

Industries Affected

IVD Instrument Manufacturers (especially export-oriented firms)
These companies are impacted because PMP is commonly used in sensor housings and fluid-path components of blood gas analyzers and ECMO monitoring devices. The new requirement delays CE IVDR certification timelines, particularly for products already in registration review. Affected firms must now revise their technical documentation, retest materials, and potentially adjust product labeling or risk management files.

PMP Material Suppliers and Compounders
The requirement places new emphasis on medical-grade purity and traceability of PMP resin. Suppliers serving IVD device makers may face increased demand for certified lots with full extractables/leachables profiles and documented manufacturing controls aligned with ISO 10993-17. Current commercial-grade PMP may no longer suffice without supplemental validation.

Contract Manufacturing and Assembly Service Providers
Firms involved in assembling PMP-based sensor modules or integrating them into larger IVD systems must verify whether their existing material declarations and process validations meet the updated biocompatibility expectations. Requalification of assembly processes—including cleaning, bonding, and sterilization—may be necessary if those steps affect leachable profiles.

Regulatory Affairs and Certification Support Providers
Consultancies and notified body support services must update internal checklists and client guidance to include PMP-specific biocompatibility evidence. This affects gap assessments, audit preparation, and pre-submission reviews—particularly for clients targeting Class C or D IVDs under IVDR where biological safety evidence carries higher scrutiny.

What Relevant Companies or Practitioners Should Focus On — And How to Respond

Monitor official updates from TÜV Rheinland and other Notified Bodies

The May 10 notice is a technical bulletin—not a formal amendment to IVDR—but its adoption by TÜV Rheinland suggests alignment with broader NB expectations. Companies should track whether other Notified Bodies (e.g., BSI, Dekra, SGS) issue similar clarifications, and whether the European Commission or MDCG releases harmonized guidance referencing PMP.

Review current PMP component specifications and test history

Manufacturers should identify all PMP-containing parts in IVDR-bound products, cross-check existing ISO 10993 data (if any), and determine whether prior tests were conducted per ISO 10993-5/-10 editions applicable to IVDR (e.g., 2023 or later). Retesting may be needed if legacy studies lack adequate justification of sample preparation, extraction conditions, or biological endpoints.

Distinguish between regulatory signal and immediate compliance obligation

This notice applies to new and pending IVDR submissions—not retroactively to CE-marked legacy devices under IVDD. However, significant design changes to existing devices (e.g., material substitution or reprocessing validation) could trigger reassessment. Companies should assess whether their current portfolio falls under ‘new’ or ‘legacy’ scope before allocating resources.

Engage early with material suppliers and testing labs

Lead times for ISO 10993-5/-10 testing—including extractables profiling, cytotoxicity assays, and skin sensitization studies—can exceed 12 weeks. Firms should initiate supplier discussions on PMP lot traceability and coordinate with accredited labs (e.g., those with ISO/IEC 17025 scope covering ISO 10993) to secure testing capacity ahead of submission deadlines.

Editorial Perspective / Industry Observation

Observably, this notice reflects an evolving interpretation of biological safety expectations under IVDR—not a newly introduced legal requirement, but a tightening of evidentiary thresholds for polymers used in critical IVD monitoring functions. Analysis shows that TÜV Rheinland’s position aligns with increasing regulatory focus on patient-contact duration, fluid pathway complexity, and cumulative exposure risks in life-supporting diagnostics. From an industry perspective, it is more accurately understood as a procedural signal than an immediate market barrier: while it adds verification steps, it does not prohibit PMP use outright. Instead, it elevates the bar for material characterization and shifts responsibility toward upstream supply chain transparency. Continued attention is warranted as similar interpretations may emerge across other high-performance polymers (e.g., PVDF, COC) in IVDR-regulated contexts.

This notice underscores how IVDR implementation continues to drive granular, application-specific refinements in conformity assessment—even for well-established materials. It highlights that regulatory readiness now depends less on broad material classifications and more on context-driven biological safety dossiers. Currently, it is more appropriate to interpret this development as a calibration of existing requirements rather than a fundamental policy shift.

Source: TÜV Rheinland Technical Bulletin, issued May 10, 2026.
Note: Ongoing observation is recommended regarding potential alignment by other Notified Bodies and future MDCG guidance referencing polymer-specific biocompatibility expectations under IVDR.